Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer

The clinical application of immunotherapy is the milestone of cancer treatment. However, some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple cancer cells and is associated with poor prognosis. It is the key enzyme of prostaglandin E (PGE2) that has been prov...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2021-02, Vol.11, p.637504-637504
Main Authors: Pu, Dan, Yin, Liyuan, Huang, Lin, Qin, Changlong, Zhou, Yuwen, Wu, Qiang, Li, Yan, Zhou, Qinghua, Li, Lu
Format: Article
Language:English
Subjects:
cancer
celecoxib
combination therapy
cyclooxygenase-2
immunotherapy
Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The clinical application of immunotherapy is the milestone of cancer treatment. However, some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple cancer cells and is associated with poor prognosis. It is the key enzyme of prostaglandin E (PGE2) that has been proved to promote the development, proliferation and metastasis of tumor cells. Recent studies further find the PGE2 in tumor microenvironment (TME) actively triggers tumor immune evasion many ways, leading to poor response of immunotherapy. COX-2 inhibitor is suggested to restrain the immunosuppression of PGE2 and may enhance or reverse the response of immune checkpoint inhibitors (ICIs). This review provides insight into the mechanism of COX-2/PGE2 signal in immunosuppressive TME and summarizes the clinical application and trials in cancer treatment.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.637504